Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)
Close on Nov 17, 2026Market cap $3.41BP/E –Yield –
Iovance Biotherapeutics cash
Cash and short-term investments held at the end of each period.
Iovance Biotherapeutics's cash was $297.67M at Jun 30, 2026. For fiscal 2025 it was $296.98M, down 10.0% from the year before. Over ten years it grew 11.1% a year on average. The highest annual figure on record is $635.00M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $296.98M | -10.0% |
| FY2024 | Dec 31, 2024 | $330.14M | +18.0% |
| FY2023 | Dec 31, 2023 | $279.87M | -41.5% |
| FY2022 | Dec 31, 2022 | $478.28M | -6.3% |
| FY2021 | Dec 31, 2021 | $510.49M | -19.6% |
| FY2020 | Dec 31, 2020 | $635.00M | +103.2% |
| FY2019 | Dec 31, 2019 | $312.53M | -19.1% |
| FY2018 | Dec 31, 2018 | $386.37M | – |
| FY2017 | Dec 31, 2017 | $0 | -100.0% |
| FY2016 | Dec 31, 2016 | $166.50M | +60.6% |
| FY2015 | Dec 31, 2015 | $103.70M | +130.9% |
| FY2014 | Dec 31, 2014 | $44.91M | +128.3% |
| FY2013 | Dec 31, 2013 | $19.67M | – |
| FY2012 | Dec 31, 2012 | $0 | -100.0% |
| FY2011 | Dec 31, 2011 | $510.22K | -60.5% |
| FY2010 | Dec 31, 2010 | $1.29M | +15553.0% |
| FY2009 | Dec 31, 2009 | $8.26K | +184.2% |
| FY2008 | Dec 31, 2008 | $2.91K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $297.67M | -1.2% |
| Q1 FY2026 | Mar 31, 2026 | $313.44M | -12.9% |
| Q4 FY2025 | Dec 31, 2025 | $296.98M | -10.0% |
| Q3 FY2025 | Sep 30, 2025 | $300.80M | -24.3% |
| Q2 FY2025 | Jun 30, 2025 | $301.18M | -27.0% |
| Q1 FY2025 | Mar 31, 2025 | $359.71M | +1.0% |
| Q4 FY2024 | Dec 31, 2024 | $330.14M | +18.0% |
| Q3 FY2024 | Sep 30, 2024 | $397.49M | +10.0% |
| Q2 FY2024 | Jun 30, 2024 | $412.54M | +64.4% |
| Q1 FY2024 | Mar 31, 2024 | $356.20M | -43.1% |
| Q4 FY2023 | Dec 31, 2023 | $279.87M | -41.5% |
| Q3 FY2023 | Sep 30, 2023 | $361.37M | +0.3% |
| Q2 FY2023 | Jun 30, 2023 | $250.89M | -40.9% |
| Q1 FY2023 | Mar 31, 2023 | $626.29M | +29.9% |
| Q4 FY2022 | Dec 31, 2022 | $478.28M | -6.3% |
| Q3 FY2022 | Sep 30, 2022 | $360.17M | -37.5% |
| Q2 FY2022 | Jun 30, 2022 | $424.46M | -35.3% |
| Q1 FY2022 | Mar 31, 2022 | $482.19M | -21.0% |
| Q4 FY2021 | Dec 31, 2021 | $510.49M | -19.6% |
| Q3 FY2021 | Sep 30, 2021 | $576.45M | -19.9% |
| Q2 FY2021 | Jun 30, 2021 | $656.37M | -15.6% |
| Q1 FY2021 | Mar 31, 2021 | $610.20M | +142.9% |
| Q4 FY2020 | Dec 31, 2020 | $635.00M | +103.2% |
| Q3 FY2020 | Sep 30, 2020 | $719.70M | +98.9% |
| Q2 FY2020 | Jun 30, 2020 | $777.40M | +92.4% |
| Q1 FY2020 | Mar 31, 2020 | $251.20M | -34.9% |
| Q4 FY2019 | Dec 31, 2019 | $312.53M | -19.1% |
| Q3 FY2019 | Sep 30, 2019 | $361.90M | +101.9% |
| Q2 FY2019 | Jun 30, 2019 | $404.10M | +1243.3% |
| Q1 FY2019 | Mar 31, 2019 | $385.93M | +29.9% |
| Q4 FY2018 | Dec 31, 2018 | $386.37M | – |
| Q3 FY2018 | Sep 30, 2018 | $179.26M | +9.7% |
| Q2 FY2018 | Jun 30, 2018 | $30.08M | -76.7% |
| Q1 FY2018 | Mar 31, 2018 | $297.10M | +101.8% |
| Q4 FY2017 | Dec 31, 2017 | $0 | -100.0% |
| Q3 FY2017 | Sep 30, 2017 | $163.40M | -8.9% |
| Q2 FY2017 | Jun 30, 2017 | $129.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $147.20M | – |
| Q4 FY2016 | Dec 31, 2016 | $166.50M | – |
| Q3 FY2016 | Sep 30, 2016 | $179.30M | – |
See a number that looks wrong?